Immune-based therapies continue to show promising signals for patients with small cell lung cancer (SCLC) and mesothelioma, but better predictive biomarkers are needed to determine who is most likely to benefit, according to Justin F. Gainor, MD. The rationale for immunotherapy in SCLC is growing because it is a very molecularly complex disease, … [Read more...]
Clinical Safety and Activity of Pembrolizumab in Patients With Malignant Pleural Mesothelioma
BACKGROUND Malignant pleural mesothelioma is a highly aggressive cancer with poor prognosis and few treatment options following progression on platinum-containing chemotherapy. We assessed the safety and efficacy of pembrolizumab (an anti-programmed cell death receptor 1 [PD-1] antibody) in advanced solid tumours expressing programmed cell death … [Read more...]